Ludwigshafen, Germany

Dora I Reicheneder

This inventor holds 1 USPTO granted patent. Top assignee: Basf Aktiengesellschaft. Active years: 1989.


% Patents Active = 100.0

Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1989

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Dora I Reicheneder: Innovator in Pharmaceutical Chemistry

Introduction

Dora I Reicheneder is a prominent inventor based in Ludwigshafen, Germany. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic applications. Her work focuses on creating innovative solutions for various medical conditions.

Latest Patents

Dora I Reicheneder holds a patent for "Novel pyridazinone-imines and their physiologically tolerated addition." This patent describes novel 1-phenyl-4(1H)-pyridazinone-imines that are substituted at the imine nitrogen. The patent also covers their addition salts with physiologically tolerated acids, processes for their preparation, pharmaceutical formulations containing these compounds, and their use as drugs, particularly as antidepressants, antiparkinson drugs, and antihypotonic agents. She has 1 patent to her name.

Career Highlights

Dora has built a successful career at BASF Aktiengesellschaft, a leading global chemical company. Her innovative research has contributed to advancements in drug development and has the potential to improve the quality of life for many patients.

Collaborations

Throughout her career, Dora has collaborated with notable colleagues, including Hans-Juergen Teschendorf and Martin Traut. These collaborations have fostered a productive environment for innovation and research.

Conclusion

Dora I Reicheneder is a trailblazer in the field of pharmaceutical chemistry, with a focus on developing novel therapeutic compounds. Her contributions to the industry highlight the importance of innovation in improving healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…